Ulisse Biomed Logo

Ulisse Biomed

Provides a portable platform for rapid point-of-need genetic analysis and diagnostics.

UBM | XMIL

Overview

Corporate Details

ISIN(s):
IT0005451213 (+1 more)
LEI:
815600F9C180B297BE35
Country:
Italy
Address:
VIA AQUILEIA, 17, 33100 UDINE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ulisse Biomed is a global biotechnology company focused on decentralizing genetic analysis and diagnostics. Its core offering is the proprietary Hyris System™, a portable, smart platform that enables rapid real-time PCR testing of biological samples in any setting. By making genetic analysis simpler and more accessible, the company facilitates the shift from centralized laboratories to point-of-need applications. Ulisse Biomed serves clients in the healthcare, diagnostics, agrifood, and nutraceutical sectors. Additionally, it provides OEM and development services for third-party kit developers and is engaged in creating innovative theranostic and therapeutic solutions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-01 17:14
Pre-Annual General Meeting Information
RINVIO ASSEMBLEA STRAORDINARIA IN SECONDA CONVOCAZIONE
Italian 205.4 KB
2025-11-24 23:39
Earnings Release
ULISSE BIOMED S.P.A. RICEVE UN ORDINE SIGNIFICATIVO PER LA FORNITURA DI PRODOTT…
Italian 172.2 KB
2025-11-21 15:31
Share Issue/Capital Change
SOTTOSCRITTO PER EURO 537.200 L’AUMENTO DI CAPITALE SOCIALE DELIBERATO DAL CONS…
Italian 184.5 KB
2025-11-15 12:14
Regulatory Filings
CONVOCAZIONE DELL’ASSEMBLEA STRAORDINARIA DEGLI AZIONISTI E DEPOSITO DELLA DOCU…
Italian 200.9 KB
2025-11-13 19:29
Regulatory Filings
IL CONSIGLIO DI AMMINISTRAZIONE ESERCITA LA DELEGA AD AUMENTARE IL CAPITALE SOC…
Italian 242.0 KB
2025-10-31 17:55
Share Issue/Capital Change
CHIUSURA OTTAVO PERIODO DI ESERCIZIO WARRANT
Italian 222.3 KB
2025-09-30 18:02
Share Issue/Capital Change
APERTURA DELL’OTTAVO PERIODO DI ESERCIZIO DEI “WARRANT ULISSE BIOMED S.P.A. 202…
Italian 208.5 KB
2025-09-30 17:54
Report Publication Announcement
IL CONSIGLIO DI AMMINISTRAZIONE DI ULISSE BIOMED APPROVA LA RELAZIONE SEMESTRAL…
Italian 683.5 KB
2025-09-05 20:05
Regulatory Filings
ULISSE BIOMED S.P.A. INDIVIDUA BANCA FINNAT COME INTERMEDIARIO PER LA NEGOZIAZI…
Italian 207.5 KB
2025-07-31 19:58
Share Issue/Capital Change
SIGNED AN INVESTMENT AGREEMENT WITH U.S. INVESTOR GLOBAL CORPORATE FINANCE
English 323.4 KB
2025-07-31 19:37
Share Issue/Capital Change
SOTTOSCRITTO UN ACCORDO DI INVESTIMENTO CON L’INVESTITORE STATUNITENSE GLOBAL C…
Italian 540.4 KB
2025-07-23 18:37
Share Issue/Capital Change
COMUNICAZIONE DI VARIAZIONE DEL CAPITALE SOCIALE
Italian 255.4 KB
2025-06-30 17:38
Share Issue/Capital Change
“WARRANT ULISSE BIOMED S.P.A. 2021-2026”: RISULTATI DEL SETTIMO PERIODO DI ESER…
Italian 241.8 KB
2025-05-30 12:21
Share Issue/Capital Change
APERTURA DEL SETTIMO PERIODO DI ESERCIZIO DEI “WARRANT ULISSE BIOMED S.P.A. 202…
Italian 188.9 KB
2025-05-12 12:02
Report Publication Announcement
WEBSIM INIZIA LA COPERTURA DEL TITOLO UBM
Italian 181.7 KB

Automate Your Workflow. Get a real-time feed of all Ulisse Biomed filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ulisse Biomed

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ulisse Biomed via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CAMBRIDGE COGNITION HOLDINGS PLC Logo
Digital brain health assessment platform for CNS clinical trials and research.
United Kingdom
COG
Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan
4575
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland
CTX
Cardiff Oncology, Inc. Logo
Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
AI-powered epigenetic and genetic tests for early detection of heart disease risk.
United States of America
CDIO
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.
United States of America
SAVA
Celcuity Inc. Logo
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
United States of America
CELC
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America
CVM
Celyad Oncology SA Logo
Clinical-stage biotech developing CAR T therapies for solid and blood cancers.
Belgium
CYAD

Talk to a Data Expert

Have a question? We'll get back to you promptly.